Loading...
OTCM
BDPT
Market cap308kUSD
Dec 05, Last price  
0.03USD
1D
25.00%
1Q
-24.21%
Jan 2017
-85.24%
IPO
-99.15%
Name

BioAdaptives Inc

Chart & Performance

D1W1MN
OTCM:BDPT chart
P/E
P/S
24.34
EPS
Div Yield, %
Shrs. gr., 5y
-15.12%
Rev. gr., 5y
4.98%
Revenues
13k
-55.65%
00019,044009,93416,32719,77617,17628,56512,669
Net income
-899k
L+26.18%
-17,780-2,575,433-227,432-171,348-62,499-1,406,663-438,246-1,077,572-1,322,342-1,080,119-712,466-899,000
CFO
-250k
L+11.50%
-26,047-58,628-7200-402,145-168,120-106,889-158,651-227,259-223,773-249,517

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BioAdaptives, Inc. markets and distributes natural plant and algal-based products for humans and animals. The company focuses on offering health and wellness products, such as dietary supplements. It offers PrimiCell, PluriPain, PrimiLungs, PrimiLive, and PrimiSleep, as well as markets Lung Flute for humans; Canine Regen and Equine Regen for dogs and horses, as well as base formulations, including Equine All-in-One to trainers, horse owners and boarding stables; and All-in-One products, which combine minerals, vitamins, amino acids, and other botanicals with the Regen compounds. The company was formerly known as APEX 8 Inc. and changed its name to BioAdaptives, Inc. in September 2013. BioAdaptives, Inc. was incorporated in 2013 and is based in Las Vegas, Nevada.
IPO date
Jul 09, 2014
Employees
3
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT